Environmental risk assessment of gene therapy
products and recombinant vaccines
Evaluation of new techniques and environmental risk assessment for research, clinical trials, field releases or market application
Advice on biosafety and prevention of misuse in biological science as member of the Forum for Genetic Research of the Swiss Academy of Sciences 2006-2020
Advice on environmental risk assessment reports for the potential application of the placing on the market of genetically modified live viral vaccines since 2013. Examples from industry upon request
Design of environmental risk assessment reports for the application of the placing on the market of genetically modified cell therapy since 2013. Examples from industry upon request
Design of environmental risk assessment reports for the application of clinical trials and the placing on the market of ATMPs and recombinant vaccines, since 2006. Examples from industry upon request
Evaluation of safe application of ATMPs and recombinant vaccines regarding environmental safety and safety for medicinal personnel and contact persons, since 2001. Examples from industry upon request